Skip to main content

Table 3 Toxicity for patients treated with pemetrexed plus platinum (n = 53).

From: Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

Adverse event Any grade ≥ 1 Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 26 (49.1) 10 (18.9) 11 (20.8) 3 (5.7) 2 (3.8)
Neutropenia 20 (37.7) 6 (11.3) 9 (17.0) 3 (5.7) 2(3.8)
Thrombocytopenia 17 (32.1) 11 (20.8) 2 (3.8) 2 (3.8) 2 (3.8)
Anemia 8 (15.1) 4 (7.5) 4 (7.5) - -
ALT/AST 3 (5.7) 3 (5.7) - - -
Nausea/Vomiting 26 (49.1) 16 (30.2) 9 (17.0) 1 (1.9) -
Diarrhea 1 (1.9) - - - 1 (1.9)
Creatinine 1 (1.9) - - - 1 (1.9)
Pyrexia 5 (9.4) 4 (7.5) 1 (1.9) - -
Fatigue 10 (18.9) 10 (18.9) - - -
Rash 5 (9.4) 1 (1.9) 3 (5.7) 1 (1.9) -
Inflammation 3 (5.7) - 3 (5.7) - -
  1. Data are number of patients with rates in brackets